High Court Quashes Prosecution Following Procedural Lapses in Drug Testing

In a significant ruling for pharmaceutical compliance, the High Court of Jammu & Kashmir and Ladakh has quashed criminal proceedings initiated against the Managing Director of Jacksons Laboratories Pvt. Ltd., citing a violation of the accused's statutory right to re-test drug samples.

Case Background

The dispute originated in December 2013, when a Drug Inspector inspected the premises of M/S J.M. Traders in Pulwama and collected samples of the drug Molcin plus . Subsequent testing by the Government Analyst branded the drug "not of standard quality."

Following this report, the petitioner, Sudhir Kumar, was issued a notice by the Drug Inspector. Kumar promptly challenged the findings and formally notified the authorities of his intent to adduce evidence in controversion of the analyst's report, invoking section 25(4) of the Drugs and Cosmetics Act, 1940 . Although the manufacturer communicated this intention early in 2014, the authorities failed to facilitate a timely re-analysis at the Central Drugs Laboratory. By the time the petitioner appeared before the Chief Judicial Magistrate in mid-2016, the medicine’s shelf life had already expired—effectively foreclosing any possibility for scientific re-testing.

Arguments on Procedure

The petitioner argued that the failure to act on his request for re-testing deprived him of a valuable statutory protection. He contended that once the accused signifies an intention to controvert the report, the mechanism for re-testing under Section 25 (4) must be strictly adhered to.

Conversely, the prosecution maintained that the statutory provisions do not mandate an automatic re-test on mere notification, arguing that the court and the authorities possess discretion in deciding whether to send samples for analysis at the Central Drugs Laboratory.

Legal Analysis

Justice Sanjeev Kumar, presiding over the case, underscored that while the court and the authorities hold discretion, that discretion must be exercised to uphold the principles of natural justice. The court noted that the Drug Inspector’s failure to act with promptitude effectively rendered the petitioner’s statutory right illusory. By delaying the initiation of the complaint until after the drug’s expiry, the state deprived the accused of the chance to prove his innocence through independent forensic evaluation.

Key Observations

The judgment clarifies the reach of , emphasizing, " If the sample has already been tested or analysed in the Central Drugs Laboratory, then there is no requirement to send it again... However, where the initial report is by the Government Analyst... the Inspector (complainant), shall have the option to make a request to the Court for sending the sample... for testing and analysis. "

Furthermore, the court remarked: - "The retesting or re-analysis of the sample which stood already tested or analysed by the Government Analyst is always on the request of either the complainant or the accused." - "The Drug Inspector concerned, who had already been intimated and requested in this regard, failed to ensure that the retained portion of the sample for the Court is put to test or analysed... during the currency of its shelf life."

The Final Decision

Concluding that the prosecution’s inaction resulted in an abuse of the process of law, the High Court allowed the petition. The court quashed the complaint and the order of cognizance, emphasizing that a criminal trial cannot proceed when the state’s procedural failures have permanently prejudiced the accused's ability to defend themselves against technical allegations.

This ruling serves as a stern reminder to regulatory agencies that the efficacy and validity of criminal charges in pharmaceutical cases depend heavily on adherence to the procedural timelines prescribed by the Drugs and Cosmetics Act .